Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $3.00.

STTK has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Wall Street Zen raised Shattuck Labs from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Leerink Partners reduced their price target on shares of Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating on the stock in a research report on Thursday, August 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Finally, Wedbush assumed coverage on shares of Shattuck Labs in a research report on Monday, September 8th. They issued an "outperform" rating and a $4.00 price objective for the company.

Check Out Our Latest Analysis on STTK

Shattuck Labs Trading Up 5.2%

NASDAQ STTK opened at $2.03 on Friday. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $2.71. The company has a 50 day moving average of $2.06 and a 200-day moving average of $1.37. The firm has a market cap of $128.46 million, a price-to-earnings ratio of -1.99 and a beta of 1.88.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $1.00 million during the quarter. On average, analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current year.

Insider Activity at Shattuck Labs

In related news, Director Mona Ashiya purchased 6,306,127 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the acquisition, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Orbimed Advisors Llc acquired 6,306,127 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the transaction, the director directly owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 12.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Shattuck Labs

Several large investors have recently made changes to their positions in STTK. Turtle Creek Wealth Advisors LLC acquired a new position in Shattuck Labs in the third quarter valued at approximately $29,000. Virtu Financial LLC acquired a new position in Shattuck Labs in the 3rd quarter worth $38,000. AQR Capital Management LLC boosted its position in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock worth $41,000 after buying an additional 31,355 shares during the period. Qube Research & Technologies Ltd acquired a new position in Shattuck Labs during the 2nd quarter worth approximately $44,000. Finally, Squarepoint Ops LLC acquired a new position in Shattuck Labs during the third quarter worth $46,000. Institutional investors and hedge funds own 58.74% of the company's stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Featured Articles

• Five stocks we like better than Shattuck Labs
• 3 REITs to Buy and Hold for the Long Term
• A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
• Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
• 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
• Financial Services Stocks Investing
• Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Shattuck Labs Right Now?

Before you consider Shattuck Labs, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shattuck Labs wasn't on the list.

While Shattuck Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here